



PTO/A820 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

**U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE**

Information Disclosure Statement – PTO 1449 (Modified)

Sheet 1 of 2

<b>INFORMATION DISCLOSURES STATEMENT BY APPLICATION</b> (use as many sheets as necessary)	Docket Number (Optional) 53047/31628	Application Number 10/083,283
	Applicant Dugan et al.	
	Filing Date February 23, 2002	Group Art Unit 1646-1614

## **U.S. PATENT DOCUMENTS**

**RECEIVED**

MAY 28 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		G.S. Roth, et al., "Effects Of Reduced Energy Intake On The Biology Of Aging; The Primate Model"; European Journal of Clinical Nutrition (2000); 54, Suppl 3, S15-S20.
		G.S. Roth, et al., "Caloric Restriction in Primates and Relevance to Humans"; Annals New York Academy of Sciences; (April 2001) 305-315.
		Constance Holden, "The Quest to Reserve Time's Toll" ; Science Vol. 295 (February 8, 2002), 1032-1033.
		Joseph Knoll, "The Striatal Dopamine Dependency of Life Span in Male Rats. Longevity Study With (-) Deprenyl"; Mechanisms of Ageing and Development, 46; (1988) 237-262.
		K. Kitani et al., "Chronic Treatment of (-) Deprenyl Prolongs The Life Span Of Male Fischer 344 Rats. Further Evidence"; Life Sciences, Vol. 52; (November 6, 1992), 281-288.
		M.C. Carrillo et al., "A High Dose of Long Term Treatment With Deprenyl Loses Its Effect On Antioxidant Enzyme Activities As Well As On Survivals Of Fischer-344 Rats"; Life Sciences 67; (2000), 2539-2548

**EXAMINER**

**DATE CONSIDERED**

ED  
1/6/05

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/42 (08-00)

**Approved for use through 10/31/2002. OMB 0651-0031**  
**U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE**

Sheet 2 of 2

<b>37 CFR 1.501</b> <b>INFORMATION DISCLOSURE CITATION</b> <b>IN A PATENT</b> (Use several sheets if necessary)	Docket Number (Optional) <b>53047/31628</b>	Patent Number <b>10/083,283</b>
	Applicant <b>Dugan et al.</b>	
	Filing Date <b>February 23, 2002</b>	Group Art Unit <b>1646-1614</b>

## **U.S. PATENT DOCUMENTS**

**RECEIVED**

MAY 28 2002

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	ISSUE DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		Donald K. Ingram, et al., "Chronic Treatment Of Aged Mice With L-Deprenyl Produces Marked Striatal MAO-B Inhibition But No Beneficial Effects on Survival, Motor Performance, or Nigral Lipofuscin Accumulation"; Neurobiology of Aging, Vol. 14: (1993) 431-440.
		R.G. Jordens et al., "Prolongation of Life in an Experimental Model of Aging in Drosophila Melanogaster"; Neurochemical Research, Vol. 24, No. 2; (1999) 227-233.
		W. Birkmayer, et al., "Increased Life Expectancy Resulting from Addition of L-Deprenyl to Madopar Treatment in Parkinson's Disease: A Longterm Study"; Journal of Neural Transmission, 64; (1985) 113-127.
		Y. Ben-Shlomo, et al., "Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease; further results of randomized trial and confidential inquiry"; BMJ Vol. 316 (April 18, 1998); 1191-1196.
		P.J. Krusic, et al., "Radical Reactions of C60"; Science Vol. 254; (November 22, 1991) 1183-1185.
		Laura Dugan et al., "Rapid microplate assay for superoxide scavenging efficiency"; Journal of Neuroscience Methods 97; (2000) 139-144.

**EXAMINER**

**DATE CONSIDERED**

1901789

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/083,283
Sheet	1	of	1	Filing Date	February 23, 2002
				First Named Inventor	Dugan et al.
				Art Unit	1646-1614
				Examiner Name	Not Yet Assigned R.H.Sailey
				Attorney Docket Number	53047-31628

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US- 5,739,376	04-14-1998	Bingel	
	AB	US- 6,538,153 B1	03-25-2003	Hirsch et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	AC	WO-97/46227	12-11-1997	Choi et al.	T <sup>6</sup>

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
		Number <sup>2</sup>	Author	Title	Date
	AD	DUGAN, L. et al., Carboxyfullerenes as Neuroprotective Agents, Proc. Natl. Acad. Sci. August 1997, 94: 9434-9439			
	AE	BOSSI, S. et al., Fullerene Derivatives: An Attractive Tool for Biological Applications, Euro. J. of Med. Chem. 2003, 38: 913-923			
	AF	PCT International Search Report dated August 12, 2004			

Examiner Signature	<i>R.H.Sailey</i>	Date Considered	1/6/05
--------------------	-------------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

The PTO did not receive the following listed Items(s) all references